Research Analysts' Ratings Reiterations for April, 29th (ABBV, BJRI, CNA, GPK ... Zolmax In the meantime, the pipeline is advancing well, with a number of meaningful data readouts expected later this year (e.g., ABT-199 at ASCO, initial Hep-C phase-3 at AASLD in November) and in 2014 (e.g., Daclizumab phase-3).” BJ's Restaurants (NASDAQ: ... |
